# Fabry Disease: Developing Drugs for Treatment Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/fabry-disease-developing-drugs-for-treatment-guidance-for-industry/37d2e0fe-939f-490c-8fec-d2753a0f2f8c

> FDA guidance document: Fabry Disease: Developing Drugs for Treatment Guidance for Industry. Issue date: August 07, 2019. Get complete insights and analysis.

---

## Details

- Title: Fabry Disease: Developing Drugs for Treatment Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-08-07
- Comment Close Date: 2019-11-06
- Last Changed: 2019-10-23
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-2973">FDA-2019-D-2973</a>

## Related Documents

- [Master Protocols for Drug and Biological Product Development](https://www.globalkeysolutions.net/guidances/guidance-document/master-protocols-for-drug-and-biological-product-development/401e65ec-7388-4389-a95a-dc8860a1ce51)
- [Labeling for Biosimilar and Interchangeable Biosimilar Products](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-and-interchangeable-biosimilar-products/54a5f712-03f5-4993-b0d7-6a1c2f261eff)
- [Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy](https://www.globalkeysolutions.net/guidances/guidance-document/mucopolysaccharidosis-type-iii-sanfilippo-syndrome-developing-drugs-for-treatment-guidance-for-industry-draft-guidance-for-industy/942f35fd-9db0-4292-9bf9-3ebc347373df)